Skip to Content
Søk Menu
cncpt-artikel_lb_atf

CLL: Needs At Least 10 Years of Follow-Up for Clinical Trials

Carsten Utoft Niemann, Consultant, PhD, Department of Hematology, Rigshospitalet, and Clinical Lecturer at the University of Copenhagen, presented highlights and Danish perspectives on CLL at the Danish Evening at EHA 2024.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Emelie Hamotal Curovic Rotbain

Dansk Aften ASH 2024: Nye fremskridt i behandling af CLL

/ Emelie Hamotal Curovic Rotbain
ASH24CLL Play the Video 03:30
Ingrid Glimelius

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Ingrid Glimelius
ASH24CLL Play the Video 02:15
Paolo Ghia

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Paolo Ghia
ASH24CLL Play the Video 03:54
Jennifer R Brown

Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

/ Jennifer R. Brown
ASH24CLL Play the Video 04:11
Florian Simon

Acalabrutinib Shows Promise for Elderly CLL Patients

/ Florian Simon
ASH24CLL Play the Video 05:20

Several Trials Showed Improvements in the Treatment of Multiple Myeloma

/ BestPractice Nordic
EHA24Myelomatose

EHA 2024: One of the Most Important for Many Years

/ BestPractice Nordic
EHA24Lymfom

The Development of New Treatment Options within AML Is Slower Than in Other Disease Areas within Hematology

/ BestPractice Nordic
AMLEHA24

New Data from EHA Shared and Discussed at Danish Evening

/ Jan Andreasen
EHA24
Back to top